Duobrii Generic Name & Formulations
Halobetasol propionate 0.01%, tazarotene 0.045%; lotion.
Corticosteroid + retinoid.
Duobrii Dosage and Administration
≥18yrs: apply a thin layer to affected areas once daily; max 50g/week. Discontinue when control is achieved. Do not occlude. Females of reproductive potential: initiate therapy during normal menses.
<18yrs: not established.
Duobrii Boxed Warnings
Not for oral, ophthalmic, or intravaginal use. Avoid use on the face, groin, or axillae. Risk of HPA axis suppression with high-potency corticosteroids, application to large surface areas, occlusive use, altered skin barrier, concomitant multiple corticosteroid-containing products, liver failure, young age; discontinue gradually or reduce dose, if occurs. Avoid use on eczematous or sunburned skin. Sun sensitivity. Increased risk of posterior subcapsular cataracts and glaucoma; monitor for visual symptoms. Treat infection if present or develops; discontinue until resolved. Reevaluate periodically. Embryo-fetal toxicity. Obtain reliable negative pregnancy test within 2wks before initiating therapy. Advise females of reproductive potential to use effective contraception during therapy. Nursing mothers: avoid direct infant exposure.
Caution with photosensitizers (eg, thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides).
Duobrii Adverse Reactions
Contact dermatitis, application site pain, folliculitis, skin atrophy, excoriation, rash, skin abrasion/exfoliation; local adverse reactions (eg, striae, telangiectasias), Cushing’s syndrome, hyperglycemia, glucosuria, HPA axis suppression (esp. in children).
Duobrii Clinical Trials
Duobrii Patient Counseling